E-DRUG Archives (by thread)

  • [e-drug] Pharmacy Regulation (cont), Pauldspivey
  • [e-drug] Cessation of trading activities at ECHO International Health, Bonnie Fundafunda
  • [e-drug] Therapeutics Letter 45: Do Single Stereoisomer Drugs Provide Value?, Ciprian Jauca
  • [e-drug] Wholesale and retail markups on essential drugs in developing countries, Libby Levison
  • [e-drug] Mefloquin for malaria prophylaxis, Markus Fritz
  • [e-drug] Essential drugs missing from market (cont), eurek
  • [e-drug] Medicines, society, and industry, e-drug
  • [e-drug] Mefloquin for malaria prophylaxis (cont), Steve Toovey
  • [e-drug] Wholesale and retail markups on essential drugs indeveloping countries (cont), Joel Lexchin
  • [e-drug] Short course in pharmacoeconomics and drug selection, David Newby
  • [e-drug] open MSF letter to Roche on nelfinavir, raffaella.ravinetto
  • [e-drug] ICIUM 2004 Preliminary Announcement, John Chalker
  • [e-drug] Analysis of South Africa's NDP process, Andy Gray
  • [e-drug] EU parliament on production for export:, James Love
  • [e-drug] Dipyrone (metamizole) and risk of agranulocytosis, Kirsten Myhr
  • [e-drug] EU clamps down on reimportation, Kirsten Myhr
  • [e-drug] Review of Pharmacist Services, Libby Roughead
  • [e-drug] Dipyrone (metamizole)(cont), Dr.L.Offerhaus
  • [e-drug] Dipyrone(metamizole) (cont), Dr.Pablo Adolfo EDas
  • [e-drug] RFI patent legislation, Despina Samara
  • [e-drug] Regulatory decisions in a globalised world, Kirsten Myhr
  • [e-drug] Messages not received by e-drug, e-drug
  • [e-drug] WHO/EDM Technical Briefing documents, graya1
  • [e-drug] Open letter to Trade Ministers, James Love
  • [e-drug] B & M Gates foundation and Microsoft, Trouiller, Patrice
  • [e-drug] WHO/EDM Technical Briefing, Dimitri Peffer
  • [e-drug] IMF and the World Bank, Dimitri Peffer
  • [e-drug] WSJ on WTO Drugs - Sydney, Ellen 't Hoen
  • [e-drug] Washington Post editorial on WTO mini in Sydney, Ellen 't Hoen
  • [e-drug] MSF on Sydney WTO meeting, ingrid.cox
  • [e-drug] access vacancy in MSF-Holland, joost.van.der.meer
  • [e-drug] WSJ on Roche's expensive ARVs, e-drug
  • [e-drug] 25 years of essential medicines, quickj
  • [e-drug] Sigmed experience in Malawi, R. Verhage
  • [e-drug] The pharmaceutical industry as a medicines provider, Kirsten Myhr
  • [e-drug] Kenya PG programmes in Tropical Medicine and Infectious Diseases, Mary Ojoo
  • [e-drug] Distance training for junior scientists, Silvia Jarchow
  • [e-drug] More on Roche vs MSF on nelfinavir, ingrid.cox
  • [e-drug] Nefazodone under investigation in the Netherlands, e-drug
  • [e-drug] 10.5 Million Children Vaccinated Against Hepatitis B, e-drug
  • [e-drug] Drug for chickens blamed for harder-to-treat food poisoning, CBGnetwork
  • [e-drug] Lessons from Malarone donation program, Beverley Snell
  • [e-drug] Consultation on pharmacogenetics and ethics, Natalie Bartle
  • [e-drug] Comments on Sydney WTO meeting, James Love
  • [e-drug] Accountability of the pharmaceutical industry, Kirsten Myhr
  • [e-drug] WTO wrestles with access to cheap drugs solution, Kirsten Myhr
  • [e-drug] Health organisation warns that kala-azar has returned to South Sudan, Kirsten Myhr
  • [e-drug] Prices of subsidised drugs, Liudas Kanapienis
  • [e-drug] No exit strategy for para 6 negotiations?, James Love
  • [e-drug] NGOs Say No to Poisonous Proposals on Paragraph 6, James Love
  • [e-drug] Bad cop, more bad cops, Geneva negotiations on para 6, James Love
  • [e-drug] Prices of subsidised drugs (cont), Joel Lexchin
  • [e-drug] Notes from Tuesday discussions on paragraph 6, James Love
  • [e-drug] Letter from 6 Latin American and Indian generics associations on paragraph 6, James Love
  • [e-drug] 7 Reasons to Reject A Bad Deal: CPTech Note to TRIPS Council Members, James Love
  • [e-drug] Act Up-Paris confronts EU Trade Commissioner, Khalil Elouardighi
  • [e-drug] Wed on para 6 negotiations: why things broke down, James Love
    • Mail converted by MHonArc 2.4.9